TELIX PHARMACEUTICALS LTD

Telix Pharma’s Aussie shares plunge, flagged by excess supply and a down‑trend, sparking caution for biotech investors amid low liquidity and market stress.

Telix Pharma’s share slide hides rising PSMA sales, FDA nod for Pixclara, and a pending merger that could boost its precision‑medicine portfolio.

Telix Pharmaceuticals’ Q3 surge and Isotope merge fuel a $1B+ precision‑oncology outlook, launching Pixclara and PSMA‑PET to lead prostate, renal & brain cancer therapy.